The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update

D Reynolds, M Kollef - Drugs, 2021 - Springer
Pseudomonas aeruginosa is a Gram-negative bacterial pathogen that is a common cause of
nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and …

The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020)

M Egi, H Ogura, T Yatabe, K Atagi, S Inoue, T Iba… - Journal of intensive …, 2021 - Springer
Abstract The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic
Shock 2020 (J-SSCG 2020), a Japanese-specific set of clinical practice guidelines for sepsis …

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the …

A Torres, MS Niederman, J Chastre… - European …, 2017 - Eur Respiratory Soc
The most recent European guidelines and task force reports on hospital-acquired
pneumonia (HAP) and ventilator-associated pneumonia (VAP) were published almost 10 …

RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with …

J Motsch, C Murta de Oliveira, V Stus… - Clinical Infectious …, 2020 - academic.oup.com
Background The β-lactamase inhibitor relebactam can restore imipenem activity against
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam …

Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société …

R Guilhaumou, S Benaboud, Y Bennis… - Critical Care, 2019 - Springer
Background Beta-lactam antibiotics (βLA) are the most commonly used antibiotics in the
intensive care unit (ICU). ICU patients present many pathophysiological features that cause …

Timing of antibiotic therapy in the ICU

MH Kollef, AF Shorr, M Bassetti, JF Timsit, ST Micek… - Critical Care, 2021 - Springer
Severe or life threatening infections are common among patients in the intensive care unit
(ICU). Most infections in the ICU are bacterial or fungal in origin and require antimicrobial …

Update of the treatment of nosocomial pneumonia in the ICU

R Zaragoza, P Vidal-Cortés, G Aguilar, M Borges… - Critical Care, 2020 - Springer
In accordance with the recommendations of, amongst others, the Surviving Sepsis
Campaign and the recently published European treatment guidelines for hospital-acquired …

Rationalizing antimicrobial therapy in the ICU: a narrative review

JF Timsit, M Bassetti, O Cremer, G Daikos… - Intensive care …, 2019 - Springer
The massive consumption of antibiotics in the ICU is responsible for substantial ecological
side effects that promote the dissemination of multidrug-resistant bacteria (MDRB) in this …

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority …

MH Kollef, M Nováček, Ü Kivistik… - The Lancet Infectious …, 2019 - thelancet.com
Background Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated
with high mortality. We assessed the efficacy and safety of the combination antibacterial …

Antibiotic stewardship in the intensive care unit

CE Luyt, N Bréchot, JL Trouillet, J Chastre - Critical care, 2014 - Springer
The rapid emergence and dissemination of antimicrobial-resistant microorganisms in ICUs
worldwide constitute a problem of crisis dimensions. The root causes of this problem are …